{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:57:05Z","timestamp":1790722625171,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41391-026-01106-7","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:34:32Z","timestamp":1773855272000},"page":"665-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving therapies, persistent gaps: a real-world look at survival trends in metastatic prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Yufan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-6669","authenticated-orcid":false,"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1106_CR3","doi-asserted-by":"publisher","unstructured":"Sondermann M, Stehr A, Hirtsiefer C, Menzel V, Buttmann-Schweiger N, Flemming PW, et al. Survival trend in metastatic prostate cancer: Two decades of real-world data on overall survival from Germany. Prostate Cancer Prostat Dis. 2026. https:\/\/doi.org\/10.1038\/s41391-026-01092-w.","DOI":"10.1038\/s41391-026-01092-w"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2500109","DOI":"10.1056\/EVIDoa2500109","volume":"4","author":"AK Morgans","year":"2025","unstructured":"Morgans AK, Roy S, Jia AY, Barata P, Zaorsky NG, Garcia JA, et al. Age and treatment intensification in metastatic hormone-sensitive prostate cancer. NEJM Evid. 2025;4:EVIDoa2500109.","journal-title":"NEJM Evid"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.pcan.4500772","volume":"8","author":"WH Hall","year":"2005","unstructured":"Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostat Dis. 2005;8:22\u201330.","journal-title":"Prostate Cancer Prostat Dis"},{"key":"1106_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","volume":"158","author":"TJ Daskivich","year":"2013","unstructured":"Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158:709\u201317.","journal-title":"Ann Intern Med"},{"key":"1106_CR7","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1200\/JCO.2016.70.7794","volume":"35","author":"P Rajan","year":"2017","unstructured":"Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: A prospective observational study. J Clin Oncol. 2017;35:3566\u201374.","journal-title":"J Clin Oncol"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/pcan.2016.74","volume":"20","author":"SA Patel","year":"2017","unstructured":"Patel SA, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D\u2019Amico AV. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer Prostat Dis. 2017;20:234\u201340.","journal-title":"Prostate Cancer Prostat Dis"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01106-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:25Z","timestamp":1790719225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01106-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01106-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}